A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

This study is testing a new experimental drug called ST-067 to see if it can safely help treat various types of advanced solid tumors. Researchers want to see how well the body responds to this drug, either on its own or when combined with other existing cancer therapies.

This trial is for adults 18 or older who have been diagnosed with advanced cancer, including certain types of skin, lung, breast, or kidney cancer. Participants must be active and generally capable of performing daily tasks without significant physical restrictions.

You will receive the experimental drug ST-067 either through an injection under the skin or an intravenous (IV) infusion into your vein. Depending on the study group, you might also receive other medications to help your immune system fight the cancer while doctors monitor your health closely throughout the process.

This study is currently recruiting patients at medical centers in Scottsdale, Arizona; Denver, Colorado; and New Haven, Connecticut. If you are interested, your medical team can help determine if a site is convenient for you.